The PERLA trial showed consistent OS benefits across various PD-L1 tumor proportion scores, favoring Jemperli over Keytruda.

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Keytruda is currently indicated in a variety of cancers ... PD-L1-low and -negative tumors who did not see success with ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Its top-selling treatment, Keytruda, will lose patent protection in a few years. Then Merck will face biosimilar competition ...

Rahway: Merck, known as MSD outside of the United States and Canada, and Moderna, Inc., announced the initiation of INTerpath ...

If you have pneumonitis with Keytruda, your doctor might prescribe corticosteroid treatment for you. Additionally, your doctor may recommend that you temporarily or permanently stop taking Keytruda.

Underpinning the return were Keytruda sales, which jumped by 17% to $7.43 billion, beating Wall Street forecasts. However, sales of Gardasil, a treatment for cancers caused by the human ...

Merck and Co. (NYSE:MRK) has posted better-than-anticipated third-quarter profit thanks to solid demand for its crucial cancer treatment Keytruda, although the drugmaker warned of ongoing sluggishness ...